- Company
- Novo Nordisk Korea appoints Kasper Roseeuw Poulsen as new GM
- by Whang, byung-woo Mar 6, 2025 05:58am
- On March 5, Novo Nordisk Korea announced the appointment of Kasper Roseeuw Poulsen as the new General Manager starting March 2025. The new GM Kasper Roseeuw Poulsen joined Novo Nordisk in 2006 and served key roles in finance, strategy, organizational development, commercial partnership, and management across Europe, South America, and Asi
- Company
- Pfizer launches JAK inhibitor for severe alopecia areata
- by Whang, byung-woo Mar 6, 2025 05:58am
- Pfizer Korea will launch a new Janus kinase (JAK) inhibitor treatment Litfulo (ritlecitinib tosilate), and set to challenge the market for severe alopecia areata. Previously launched Olumiant (baricitinib), the first drug approved in South Korea for treating adult patients with severe alopecia areata, has already settled in the market. The co
- Company
- "COVID-19 response has changed to protect high risk groups"
- by Whang, byung-woo Mar 5, 2025 06:01am
- As COVID-19 transitioned to the endemic phase, an important issue has arisen regarding 'how' to prevent and respond to the disease, unlike the initial period focused only on response. One of the big changes was the reimbursement of treatments. On October 25, 2024, The Ministry of Health and Welfare (MOHW) approved the National Health Insuranc
- Company
- Ocrevus is reimbursed for relapsing multiple sclerosis
- by Whang, byung-woo Mar 5, 2025 06:00am
- On March 4, Roche Korea announced that its multiple sclerosis treatment drug Ocrevus (ocrelizumab) will be reimbursed by Korea’s National Health Insurance from March 1. According to the new announcement, Ocrevus will be covered as a monotherapy for patients with relapsing multiple sclerosis, which includes ▲patients with relapsing-remit
- Company
- Pfizer’s sales fall 76% in 2 yrs with the end of pandemic
- by Son, Hyung Min Mar 5, 2025 06:00am
- Pfizer Korea’s sales are on a downward trend. The company's sales have plummeted by 76% in 2 years. The analysis is that the demand for COVID-19 vaccines and treatments has fallen sharply, which has affected the decline in sales. Pfizer Korea aims to make a rebound in sales with new products such as Prevnar 20, a new pneumococcal vaccine, a
- Company
- Reimbursement possible for Long-acting HIV treatment in KOR
- by Whang, byung-woo Mar 4, 2025 05:57am
- Expectations are growing in the clinical field with the imminent reimbursement of the long-acting HIV (human immunodeficiency virus) treatment ‘Vocabria+Rekambys’ combination in Korea. It has been more than two years since the combination was approved in Korea, but it has not yet been released on the market due to hurdles including costs.
- Company
- Potential blockbuster drug Kerendia…1yr since reimbursement
- by Whang, byung-woo Mar 4, 2025 05:57am
- The prescription performance of Kerendia (finerenone), Bayer’s treatment for chronic kidney disease in adults with type 2 diabetes, has been increasing since it was granted reimbursement last year. With its monthly sales recording KRW 1 billion in the last month of last year, the drug is rapidly building up its performance, and given its gr
- Company
- Commercialization of PAH drug 'Winrevair' imminent
- by Eo, Yun-Ho Mar 4, 2025 05:57am
- The new drug 'Winrevair' for pulmonary arterial hypertension (PAH) is anticipated to land in South Korea. According to industry sources, MSD Korea's Winrevair (sotatercept), the world's first inhibitor therapy to treat PAH, has passed the secondary evaluation for the approval-reimbursement linkage process and now enters the last phase of
- Company
- Will COVID-19 vaccines be included in the NIP?
- by Moon, sung-ho Feb 28, 2025 05:58am
- The final results are gaining attention as the Korean government considers including COVID-19 vaccine to the National Immunization Program (NIP). The news presents a favorable opportunity for global pharmaceutical companies with vaccines. Consequently, these companies are focusing on publicizing the socioeconomic losses of COVID-19. Acc
- Company
- Lunit presents AI breast cancer Dx results at ECR 2025
- by Whang, byung-woo Feb 28, 2025 05:58am
- &160;On the 27th, Lunit, a medical artificial intelligence (AI) company, announced that it has presented 15 latest research achievements in the field of breast cancer diagnosis at the European Congress of Radiology 2025 (ECR 2025), which is being held in Vienna, Austria until the 2nd of next month. At the conference, Lunit presented 13 o
